Skip to Search
Skip to Navigation
Skip to Main Content
Skip to Footer
About Us
Life Sciences Publications
Our Medicines
Topic Articles
Topic Discussions
Login
Google Translate
Select language
English
French
Spanish
Login
Username
*
Password
*
Staff Login
×
Google Translate
Select language
English
French
Spanish
Login
Menu
Site Search
Search Options
Resources
Everything
Advanced Search
Uptodate
All
Title Search
Author
Patients & Caregivers
Healthcare Providers
Researchers & Partners
Investors
menu
About Us
Life Sciences Publications
Our Medicines
Topic Articles
Topic Discussions
Google News
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Scotiabank cuts Sage Therapeutics shares target after Phase 2 trial setback By Investing.com - Investing.com
Scotiabank cuts Sage Therapeutics shares target after Phase 2 trial setback - Investing.com
Scotiabank cuts Sage Therapeutics shares target after Phase 2 trial setback - Investing.com Canada
Sage Therapeutics Stock: Reassessing Investment Post Parkinson's Failure - Seeking Alpha
Sage Therapeutics Stock: Reassessing Investment Post Parkinson's Failure - Seeking Alpha
Sage Therapeutics (SAGE) PT Lowered to $19 at Scotiabank - StreetInsider.com
Nisa Investment Advisors LLC Buys 18490 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Sage Therapeutics stock target cut on trial results - Investing.com South Africa
Sage Therapeutics (SAGE) Scheduled to Post Earnings on Thursday - Defense World
Sage Therapeutics (SAGE) Scheduled to Post Earnings on Thursday - MarketBeat
Pages
« first
‹ previous
…
2
3
4
5
6
7
8
9
10
next ›
last »
×